Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery (PROJECT-BARI)
Obesity

About this trial
This is an interventional treatment trial for Obesity focused on measuring Bariatric surgery, Weight regain, Antiobesity drugs, Treatment of weight regain
Eligibility Criteria
Inclusion Criteria: Male and female subjects aged 18-70 years Had sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB) between ≥18 months and ≤10 years ago Weight regain of ≥5% relative to post-surgery nadir weight Body mass index (BMI) ≥30 kg/m2 or ≥27 kg/m2 with weight-related comorbidities Women of childbearing potential must be using appropriate contraception to avoid pregnancy throughout the study, and must have a negative pregnancy test at study entry Must be able to provide written informed consent Exclusion Criteria: Type 1 diabetes Insulin-dependent type 2 diabetes Fasting plasma glucose (FPG) ≥240 mg/dL Uncontrolled hypertension defined as systolic blood pressure (SBP) ≥150 mm Hg and/or diastolic blood pressure (DBP) ≥100 mm Hg on the average of three seated measurements after being at rest for at least 5 minutes History of significant (as determined by the investigator) and unstable cardiovascular disease including coronary artery disease, arrhythmias, severe congestive heart failure, or stroke Use of monoamine oxidase inhibitors, current or within 2 weeks Hyperthyroidism or other significant thyroid disease Angle-closure glaucoma Agitated states History of drug abuse within the past year Known hypersensitivity or idiosyncrasy to sympathomimetic amines Severe hepatic disease (non-alcoholic fatty liver disease or non-alcoholic steatohepatitis without portal hypertension or cirrhosis is acceptable) End-stage renal disease History of nephrolithiasis Serum triglycerides ≥500 mg/dL Cancer, not in remission, within the past 2 years except for adequately treated basal cell, squamous cell skin cancer, or in-situ cervical cancer History of psychosis or bipolar disorder Suicidal ideation or unstable/untreated major depressive disorder within the past year Use of antidepressant medication that has not been at stable dose for at least 3 months Hospital Anxiety and Depression Scale (HADS) score of ≥11 for depression or anxiety items Binge Eating Scale (BES) score of ≥27 Alcohol use disorder within the past year Epilepsy Currently taking phentermine or topiramate or the combination, or products containing these drugs Currently taking stimulants (e.g., Attention Deficit Hyperactivity Disorder medications) Current use of prescription or over-the-counter weight loss drugs or supplements Taking prescription or over-the-counter drugs or products, which in the opinion of the PI, could be associated with significant effects on body weight Planning additional bariatric surgery procedures in the next 13 months History of revisional bariatric surgery (revisional surgery after adjustable gastric banding is acceptable) Currently participating in another weight loss program or have plans to participate in the next 13 months Smoking cessation within the previous 3 months or plans to quit smoking in the next 13 months Pregnant or breastfeeding or planning pregnancy in the coming 13 months History of, or any existing condition that, in the opinion of the Principal Investigator, would interfere with the study outcomes or place the subject at unacceptable risk by participating in the study
Sites / Locations
- University of California Irvine Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Placebo Comparator
Group A: Topiramate 50 mg
Group B: Topiramate 100 mg
Group C: Phentermine 7.5 mg/Topiramate 50 mg
Group D: Phentermine 7.5 mg
Group E: Phentermine 15 mg
Group F: Phentermine 7.5 mg/Topiramate 50 mg
Group P: Placebo
Topiramate will be started at 25 mg daily and the dose will be increased to 50 mg daily after 15 days. Responders at Month 4 will continue the same treatment until Month 12.
Nonresponders in the topiramate group at Month 4 will be re-randomized in a 1:1 ratio to receive topiramate 100 mg or phentermine/topiramate 7.5/50 mg during Months 5-12.
Nonresponders in the topiramate group at Month 4 will be re-randomized in a 1:1 ratio to receive topiramate 100 mg or phentermine/topiramate 7.5/50 mg during Months 5-12.
Phentermine will be started at 7.5 mg daily. Responders at Month 4 will continue the same treatment until Month 12.
Nonresponders in the phentermine group at Month 4 will be re-randomized in a 1:1 ratio to receive phentermine 15 mg or phentermine/topiramate 7.5/50 mg during Months 5-12.
Nonresponders in the phentermine group at Month 4 will be re-randomized in a 1:1 ratio to receive phentermine 15 mg or phentermine/topiramate 7.5/50 mg during Months 5-12. For Group F, topiramate will be dosed at 25 mg daily for the 15 days in Month 5 and 50 mg daily thereafter,
Placebo group will receive placebo.